Skip to main content
. Author manuscript; available in PMC: 2011 Apr 15.
Published in final edited form as: Cancer Res. 2010 Apr 13;70(8):3098–3108. doi: 10.1158/0008-5472.CAN-09-3290

Table 3.

Frequency of DNA methylation at each epigenetic Marker in CRCs and its association with MSH2 expression and MSI Status

MSH2 Deficient CRC MSH2 Proficient CRC
Lynch Syndrome
(n=46)		 Sporadic MSI
(n=15)		 MSS
(n=207)		 P value
Clinical Age ≥65 7 (3) 80 (12) 51 (105) <0.0001 a
Factor <65 93 (43) 20 (3) 49 (102) <0.0001 b
0.0283 c
Gender Female 33 (15) 60 (9) 35 (73) 0.0372 a
Male 67 (31) 40 (6) 65 (134) 0.864b
0.0553c
Location Proximal 60 (15) 92 (12) 30 (60) 0.0597a
Distal 40 (10) 8 (1) 70 (143) 0.0022 b
Missing data (21) (2) (4) <0.0001 c
Genetic KRAS/BRAF BRAF mutant 0 (0) 67 (10) 5 (10) <0.0001 a
Factor Mutation KRAS mutant 24 (11) 0 (0) 35 (73) 0.0724b
Status Both wild type 76 (35) 33 (5) 60 (124) <0.0001 c
Epigenetic MSH2 Methylated 24 (11) 0 (0) 0 (0) 0.0364 a
Factor Unmethylated 76 (35) 100 (15) 100 (207) <0.0001 b
1.0c
MLH1 Methylated 4 (2) 60 (9) 0 (0) <0.0001 a
Unmethylated 96 (44) 40 (6) 100 (207) 0.00259 b
<0.0001 c
p16INK4a * Methylated 9 (4) 53 (8) 16 (33) 0.000237 a
Unmethylated 91 (40) 47 (7) 84 (174) 0.2444b
0.0003 c
p14ARF * Methylated 27 (12) 33 (5) 8 (16) 0.6545a
Unmethylated 73 (32) 67 (10) 92 (191) 0.00018 b
0.0011 c
MINT1* Methylated 34 (15) 40 (6) 9 (19) 0.6798a
Unmethylated 66 (29) 60 (9) 91 (188) <0.0001 b
0.0003 c
MINT2* Methylated 18 (8) 53 (8) 20 (41) 0.00818a
Unmethylated 82 (36) 47 (7) 80 (166) 0.8049b
0.0025 c
MINT31* Methylated 48 (21) 60 (9) 19 (40) 0.4116a
Unmethylated 52 (23) 40 (6) 81 (167) <0.0001 b
0.0002 c

All P values were calculated by the Χ2 test.

a

P values were calculated between MSH2 deficiency vs. sporadic MSI

b

P values were calculated between MSH2 deficiency vs. MSS cancers.

c

P values were calculated between sporadic MSI vs. MSS.

*

Two cases were not analyzed in MSH2 deficiency cases.